Genfit SA (GNFT) has released an update.
GENFIT announces a significant achievement with the U.S. FDA granting accelerated approval for Ipsen’s Iqirvo®, a first-in-class treatment for Primary Biliary Cholangitis (PBC). This marks the first FDA approval for a drug developed by GENFIT, with the company set to receive a €48.7 million milestone payment and up to 20% in royalties from Ipsen. The approval is expected to provide a financial boost to GENFIT, enabling the advancement of its new liver disease treatment portfolio.
For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.
